Lasso De La Vega M C, Zapater P, Such J, Sola-Vera J, Payá A, Horga J F, Pérez-Mateo M
Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Spain.
Gastroenterol Hepatol. 2002 Apr;25(4):247-50. doi: 10.1016/s0210-5705(02)70254-9.
Tamoxifen is an antiestrogenic drug that acts by binding to the estrogen receptor. The drug is used as a co-adjuvant treatment in advanced breast cancer expressing the oestrogen-receptor protein. Clinical trials of tamoxifen have shown its efficacy in reducing mortality and recurrence rates over a five-year treatment. Cases of tamoxifen-associated hepatotoxicity have been described, including cholestasis with or without cytolysis and steatohepatitis. We report the case of a female patient who developed hepatic alterations while undergoing continuous tamoxifen treatment. We also present an overview of similar cases published to date and comment on the advisability of continuing or suppressing this treatment in patients with hepatotoxicity or after a five-year treatment period.
他莫昔芬是一种抗雌激素药物，通过与雌激素受体结合发挥作用。该药物用作表达雌激素受体蛋白的晚期乳腺癌的辅助治疗。他莫昔芬的临床试验表明，在五年治疗期间，它在降低死亡率和复发率方面具有疗效。已经描述了与他莫昔芬相关的肝毒性病例，包括伴有或不伴有细胞溶解的胆汁淤积和脂肪性肝炎。我们报告了一名女性患者在接受持续他莫昔芬治疗期间出现肝脏改变的病例。我们还概述了迄今为止发表的类似病例，并对肝毒性患者或五年治疗期后继续或停止这种治疗的可取性发表评论。
